secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-01-17T23:59:59+00:00
Accession:  0001213900-24-004172
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma enters $1M convertible note financing with Lind Global Fund II
-----------------------------------------------------------------------------

- Issued $1,000,000 secured convertible note to Lind Global Fund II at $833,333 purchase price (16.7% OID).
- Conversion price: lesser of $3.50 fixed or 90% of avg three lowest VWAPs over 20 days; fixed for first 180 days.
- Warrant for 1,000,000 shares at $2.00/share exercises cashless under certain conditions; 5-year term.
- Company grants Lind 18-month right of first refusal for up to 10% of any subsequent equity financing.
- Allele Capital Partners and Wilmington Capital Securities acted as placement agents; received 25,000-share warrant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/0001213900-24-004172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024004172/ea191664-8k_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-004172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer